HomePipelinePNB-291

Pan-CCK oncology

PNB-291

IND ready

Identified preclinically as the portfolio's most efficient molecule in brain cancers such as astrocytomas and meningiomas, and positioned for gastric, liver and Lung Cancer on the basis of tumour biology.

Indications

Each indication opens its study.

Stage of development

  • PNB-291

    Brain CancerPan-CCK blocker

Graph of the stage of development of each PNB-291 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
Non-selective (pan) CCK antagonist blocking both gastrin and cholecystokinin signalling. A more potent sister molecule of PNB-091.
Key findings

Close to 90% inhibition in the MAC16 allograft model at 30 mg/kg.

Its sister molecule PNB-091 reduced U87 human brain-tumour volume in nude mice to about a third of control after 30 days, dose-dependently.

Development

Two-step synthesis, purity above 99.7%. A second fluorine atom blocks metabolism to improve oral bioavailability. ICH toxicology studies are to be launched.

Intellectual property
Patents filed in the US, Europe and rest of world; USPTO patent issued 28 December 2014.

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.